RIG-like helicase innate immunity inhibits vascular endothelial growth factor tissue responses via a type I IFN-dependent mechanism.

RATIONALE Vascular endothelial growth factor (VEGF) regulates vascular, inflammatory, remodeling, and cell death responses. It plays a critical role in normal pulmonary physiology, and VEGF excess and deficiency have been implicated in the pathogenesis of asthma and chronic obstructive pulmonary disease, respectively. Although viruses are an important cause of chronic obstructive pulmonary disease exacerbations and innate responses play an important role in these exacerbations, the effects of antiviral responses on VEGF homeostasis have not been evaluated. OBJECTIVES We hypothesized that antiviral innate immunity regulates VEGF tissue responses. METHODS We compared the effects of transgenic VEGF(165) in mice treated with viral pathogen-associated molecular pattern polyinosinic:polycytidylic acid [poly(I:C)], mice treated with live virus, and control mice. MEASUREMENTS AND MAIN RESULTS Transgenic VEGF stimulated angiogenesis, edema, inflammation, and mucin accumulation. Each of these was abrogated by poly(I:C). These inhibitory effects were dose dependent, noted when poly(I:C) was administered before and after transgene activation, and mediated by a Toll-like receptor-3-independent and RIG-like helicase (RLH)- and type I IFN receptor-dependent pathway. VEGF stimulated the expression of VEGF receptor-1 and poly(I:C) inhibited this stimulation. Poly(I:C) also inhibited the ability of VEGF to activate extracellular signal-regulated kinase-1, Akt, focal adhesion kinase, and endothelial nitric oxide synthase, and aeroallergen-induced adaptive helper T-cell type 2 inflammation. Influenza and respiratory syncytial virus also inhibited VEGF-induced angiogenesis. CONCLUSIONS These studies demonstrate that poly(I:C) and respiratory viruses inhibit VEGF-induced tissue responses and adaptive helper T-cell type 2 inflammation and highlight the importance of a RLH- and type I IFN receptor-dependent pathway(s) in these regulatory events. They define a novel link between VEGF and antiviral and RLH innate immune responses and a novel pathway that regulates pulmonary VEGF activity.

[1]  Yongjian Xu,et al.  Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. , 2010, Cytotherapy.

[2]  S. Akira,et al.  Systemic Toll-Like Receptor Stimulation Suppresses Experimental Allergic Asthma and Autoimmune Diabetes in NOD Mice , 2010, PloS one.

[3]  B. Ryffel,et al.  Double-Stranded RNA Exacerbates Pulmonary Allergic Reaction through TLR3: Implication of Airway Epithelium and Dendritic Cells , 2010, The Journal of Immunology.

[4]  E. Feldman,et al.  Vascular endothelial growth factor prevents G93A‐SOD1‐induced motor neuron degeneration , 2009, Developmental neurobiology.

[5]  Chan Sun Park,et al.  Vascular endothelial growth factor levels in induced sputum and emphysematous changes in smoking asthmatic patients. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  A. Medford,et al.  Vascular endothelial growth factor receptor and coreceptor expression in human acute respiratory distress syndrome , 2009, Journal of critical care.

[7]  J. Celedón,et al.  Association of VEGF polymorphisms with childhood asthma, lung function and airway responsiveness , 2009, European Respiratory Journal.

[8]  R. Flavell,et al.  Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13–induced tissue responses and apoptosis , 2009, The Journal of experimental medicine.

[9]  Han-Jung Park,et al.  Vascular endothelial growth factor in allergen‐induced nasal inflammation , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  L. Farkas,et al.  VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. , 2009, The Journal of clinical investigation.

[11]  M. Nugent,et al.  Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[12]  J. Kim,et al.  Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model , 2009, Clinical Rheumatology.

[13]  Wan-Uk Kim,et al.  Proinflammatory Role of Vascular Endothelial Growth Factor in the Pathogenesis of Rheumatoid Arthritis: Prospects for Therapeutic Intervention , 2009, Mediators of inflammation.

[14]  M. Sans,et al.  VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. , 2009, Gastroenterology.

[15]  Svetlana Shulga Morskaya,et al.  5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma , 2008, Nature Medicine.

[16]  I. Fidler,et al.  Targeted Induction of Lung Endothelial Cell Apoptosis Causes Emphysema-like Changes in the Mouse , 2008, Journal of Biological Chemistry.

[17]  D. Morris,et al.  Inhibitors of vascular endothelial growth factor in cancer. , 2008, Cardiovascular & hematological agents in medicinal chemistry.

[18]  C. D. Dela Cruz,et al.  Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice. , 2008, The Journal of clinical investigation.

[19]  R. Homer,et al.  Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation and mucus production. , 2008, American journal of respiratory cell and molecular biology.

[20]  R. Tuder,et al.  Vascular endothelial growth factor of the lung: friend or foe. , 2008, Current opinion in pharmacology.

[21]  Y. Gho,et al.  TH2 and TH1 lung inflammation induced by airway allergen sensitization with low and high doses of double-stranded RNA. , 2007, The Journal of allergy and clinical immunology.

[22]  K. Preissner,et al.  Flt‐1, but not Flk‐1 mediates hyperpermeability through activation of the PI3‐K/Akt pathway , 2007, Journal of cellular physiology.

[23]  E. Meurs,et al.  Regulation of Interferon Production by RIG-I and LGP2: A Lesson in Self-Control , 2007, Science's STKE.

[24]  S. Biswal,et al.  Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. , 2006, Proceedings of the American Thoracic Society.

[25]  S. Johnston,et al.  How Viral Infections Cause Exacerbation of Airway Diseases , 2006, Chest.

[26]  D. Newcomb,et al.  H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM‐1 and TLR3 expression , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  B. Ma,et al.  Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Coban,et al.  Essential role of IPS-1 in innate immune responses against RNA viruses , 2006, The Journal of experimental medicine.

[29]  Hong-Hsing Liu,et al.  The specific and essential role of MAVS in antiviral innate immune responses. , 2006, Immunity.

[30]  Christopher S. Stevenson,et al.  Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[31]  P. Coyle,et al.  Human metapneumovirus in adults: a short case series , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[32]  R. Stockley,et al.  COPD exacerbations · 2: Aetiology , 2006, Thorax.

[33]  G. Joos,et al.  Cigarette smoke-induced pulmonary emphysema in scid-mice. Is the acquired immune system required? , 2005, Respiratory research.

[34]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[35]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[36]  Min Q. Zhao,et al.  Requirement for tumor necrosis factor-receptor 2 in alveolar chemokine expression depends upon the form of the ligand. , 2005, American journal of respiratory cell and molecular biology.

[37]  R. Homer,et al.  Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung , 2004, Nature Medicine.

[38]  R. Hegele,et al.  Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. , 2003, The American journal of medicine.

[39]  D. Bates,et al.  The Role of Vascular Endothelial Growth Factor in Wound Healing , 2003, The international journal of lower extremity wounds.

[40]  K. Hirata,et al.  Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. , 2003, The American journal of medicine.

[41]  N. Voelkel,et al.  Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. , 2003, American journal of respiratory cell and molecular biology.

[42]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[43]  B. Lal,et al.  VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. , 2001, Microvascular research.

[44]  T. Seemungal,et al.  Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[45]  W. Sessa,et al.  Akt Down-regulation of p38 Signaling Provides a Novel Mechanism of Vascular Endothelial Growth Factor-mediated Cytoprotection in Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[46]  N. Anthonisen,et al.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. , 2001, American journal of respiratory and critical care medicine.

[47]  Yong Chul Lee,et al.  Vascular endothelial growth factor in patients with acute asthma. , 2001, The Journal of allergy and clinical immunology.

[48]  Q. Hamid,et al.  Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. , 2001, The Journal of allergy and clinical immunology.

[49]  D A Lynch,et al.  Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. , 2001, American journal of respiratory and critical care medicine.

[50]  N. Aoike,et al.  Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. , 2001, The Journal of allergy and clinical immunology.

[51]  B. Ma,et al.  IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. , 2000, The Journal of clinical investigation.

[52]  R. Crystal,et al.  Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. , 2000, American journal of respiratory cell and molecular biology.

[53]  T. Seemungal,et al.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations , 2000, Thorax.

[54]  Y. Fujio,et al.  Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner* , 1999, The Journal of Biological Chemistry.

[55]  A. Aguzzi,et al.  Deficient signaling in mice devoid of double‐stranded RNA‐dependent protein kinase. , 1995, The EMBO journal.

[56]  W. Sessa,et al.  Approaches for studying angiogenesis-related signal transduction. , 2008, Methods in enzymology.

[57]  S. Johnston,et al.  Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations. , 2007, Current pharmaceutical design.

[58]  D. Hui,et al.  A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. , 2007, Chest.

[59]  N. Ferrara.  The role of VEGF in the regulation of physiological and pathological angiogenesis. , 2005, EXS.

[60]  J. Wedzicha.  Role of viruses in exacerbations of chronic obstructive pulmonary disease. , 2004, Proceedings of the American Thoracic Society.